| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2005;36:670.)
© 2005 American Heart Association, Inc.
Original Contributions |
From the Department of Neurology, Graduate School of Medicine and Dentistry, Okayama University, Okayama, Japan.
Correspondence to Dr Koji Abe, Department of Neurology, Graduate School of Medicine and Dentistry, Okayama University, 2-5-1 Shikata-cho, Okayama, Okayama, 700-8558, Japan. E-mail shokon{at}cc.okayama-u.ac.jp
| Abstract |
|---|
|
|
|---|
Methods Stroke-prone spontaneous hypertensive rats (SHR-SP) were treated with pitavastatin, atorvastatin, simvastatin, or vehicle for 4 weeks. Physiological parameters, serum lipids, and infarct volumes were examined. The markers for oxidative stresses on lipids and DNA were immunohistochemically detected in vehicle-treated or simvastatin-treated SHR-SP with tMCAO.
Results Atorvastatin and simvastatin decreased infarct volumes, with simvastatin most effective. Simvastatin significantly reduced immunoreactivities for oxidative stress markers for lipids and DNA in neurons after tMCAO.
Conclusions The results suggest that the antioxidative properties of statins may be implicated in their beneficial effects against neuronal damage in cerebral ischemia.
Key Words: cerebral infarction HMG-CoA reductase inhibitors oxidative stress rats, inbred SHR
| Introduction |
|---|
|
|
|---|
| Materials and Methods |
|---|
|
|
|---|
Because simvastatin most effectively reduced infarction volumes, SHR-SP (8 weeks old) were treated with simvastatin (n=12) or vehicle (n=10) for 14 days and then underwent 90 minutes of transient middle cerebral artery occlusion (tMCAO).3 At 4 or 24 hours after the reperfusion, animals (n=5 to 7, each time point) were euthanized. Frozen brains sections were stained with hematoxylin and eosin or cresyl-violet.
All experimental procedures were approved by the Animals Committee of the Graduate School of Medicine and Dentistry, Okayama University.
Measurement of Infarct Volume
For evaluation of the infarct area of spontaneous stroke, a set of sections was immunohistochemically examined for microtubule-associated protein 2.3 Areas devoid of microtubule-associated protein 2 staining (1:500; MAB364; Chemicon, Temecula, Calif) were regarded as infarcted regions. The infarct volume of each animal was calculated by summing the infarct areas in 5 sections (National Institutes of Health Image, version 1.62a).
Immunohistochemistry for N
-(Hexanonyl)Lysine, 4-Hydroxynonenal, and 8-Hydroxy-2'-Deoxyguanosine
Immunoreactivities for N
-(hexanonyl)lysine (HEL),4 4-hydroxynonenal (4-HNE), and 8-hydroxy-2'-deoxyguanosine (8-OHdG) in tMCAO models were detected using antibodies against HEL (1:500; MHL-020; JAICA, Shizuoka, Japan), 4-HNE (1:400; MHN-020; JAICA), and 8-OHdG (1:50; MOG-020; JAICA).5 The numbers of positive cells for each marker in the 3 randomized 0.5 mm2 areas in the ischemic core were counted.
Statistical Analysis
All data are presented as mean±SD. Statistical analyses were performed using Kruskal-Wallis H test and post-hoc Mann-Whitney U test for infarct volume and physiological and biochemical parameters. For positive cell numbers, Student t test was performed. P<0.05 was considered significant.
| Results |
|---|
|
|
|---|
Infarct Volume in SHR-SP
The infarct volumes in the vehicle-treated, pitavastatin-treated, atorvastatin-treated, and simvastatin-treated groups (each n=5) were 8.7±3.7, 4.4±5.2, 3.9±3.2, and 3.3±1.1 mm3, respectively. Mann-Whitney U test showed that atorvastatin (P<0.05) and simvastatin (P<0.01) significantly decreased infarct volumes compared with vehicle, although Kruskal-Wallis H test did not reach statistical significance (P=0.11). No hemorrhage was detected in any animals.
Immunohistochemical Findings in tMCAO Animals
In simvastatin-treated animals, the intensity of staining for HEL, 4-HNE, or 8-OHdG was fainter than vehicle-treated ones (Figure A). Furthermore, simvastatin significantly decreased the number of positive cells for these oxidative stress markers (Figure B).
|
| Discussion |
|---|
|
|
|---|
We found that simvastatin was most effective against spontaneous stroke among 3 statins examined. All statins used are lipophilic, with simvastatin being the most lipophilic.6 Its strong liposolubility may result in high permeability through the blood-brain barrier to the parenchyma. Because small lesions at different stages of stroke were observed in SHR-SP, oxidative neuronal damage cannot simply be compared among the 4 groups in the spontaneous stroke model. Thus, we examined the antioxidative effect of simvastatin in tMCAO model and found substantial effects.
In the brain during and after ischemia, reactive oxygen species (ROS) impair the cell membrane by peroxidation of lipid bilayer and injure DNA, leading to cell death. Statins were shown to have antioxidant properties such as scavenging ROS,7 inhibiting ROS-induced DNA breakage,8 and restraining superoxide generation in vessel.9 Kawashima et al reported reduction of superoxide production in SHR-SP brain (nonstroke lesion) treated with cerivastatin.2 Our results suggest that statins protect the neurons against ROS-induced lipid peroxidation and DNA oxidation in the ischemic model.
Oxidative stress is profoundly involved in the pathophysiology of stroke. From the results of the present study, we believe that reduction of infarct volumes in statin-treated spontaneous stroke animals is associated with their antioxidative effect.
|
| Acknowledgments |
|---|
Received October 18, 2004; revision received November 13, 2004; accepted November 25, 2004.
| References |
|---|
|
|
|---|
-(hexanonyl)lysine in protein exposed to lipid hydroperoxide. J Biol Chem. 1999; 274: 2040620414.This article has been cited by other articles:
![]() |
J. Wang and S. Dore Heme oxygenase-1 exacerbates early brain injury after intracerebral haemorrhage Brain, June 1, 2007; 130(6): 1643 - 1652. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2005 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |